{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:09:11Z","timestamp":1793776151320,"version":"4.6.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Coronavirus disease 2019 vaccines have been instrumental in combating the global pandemic, yet their potential side effects, including autoimmune conditions such as bullous pemphigoid, remain an area of concern. This case highlights the development of bullous pemphigoid following coronavirus disease 2019 vaccination and includes a comprehensive review of similar cases reported in the literature, emphasizing its novelty and clinical significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>An elderly British man in his 80s with type 2 diabetes mellitus developed blistering lesions 21\u00a0days after receiving his third dose of coronavirus disease 2019 vaccine (Moderna). Clinical examination revealed erythematous plaques and bullae on the trunk and limbs. Histopathological evaluation and immunofluorescence confirmed the diagnosis of bullous pemphigoid. Treatment included corticosteroids, doxycycline, and immunosuppressants. Despite initial improvement, a severe flare-up necessitated hospitalization and wound care management. A systematic review identified 50 reported cases of bullous pemphigoid linked to coronavirus disease 2019 vaccination, with the Pfizer-BioNTech vaccine implicated in most cases (64%), followed by Moderna (18%). Symptom onset typically occurred after the first dose in 52% of cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case underscores the need for vigilance regarding autoimmune phenomena such as bullous pemphigoid following coronavirus disease 2019 vaccination. Awareness of such potential adverse effects is crucial to ensure timely diagnosis and management, ultimately contributing to patient safety and guiding future vaccine development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-025-05652-x","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T19:03:00Z","timestamp":1764356580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Unraveling COVID-19-vaccination-induced bullous pemphigoid: a case report and review of the literature"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-7080","authenticated-orcid":false,"given":"Savitri","family":"Chandrasekaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Kamboj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snigdha","family":"Baddepudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1798-0847","authenticated-orcid":false,"given":"Rishu","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitanya","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Sanker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7935-7333","authenticated-orcid":false,"given":"Tirth","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishan","family":"Wijenaike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"3","key":"5652_CR1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00296-021-04792-9","volume":"41","author":"T Velikova","year":"2021","unstructured":"Velikova T, Georgiev T. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. Rheumatol Int. 2021;41(3):509\u201318. https:\/\/doi.org\/10.1007\/s00296-021-04792-9.","journal-title":"Rheumatol Int"},{"issue":"2","key":"5652_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","volume":"28","author":"T Fiolet","year":"2022","unstructured":"Fiolet T, Kherabi Y, MacDonald CJ, et\u00a0al. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28(2):202\u201321. https:\/\/doi.org\/10.1016\/j.cmi.2021.10.005.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"5652_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/imm.13443","volume":"165","author":"Y Chen","year":"2022","unstructured":"Chen Y, Xu Z, Wang P, et\u00a0al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165(4):386\u2013401. https:\/\/doi.org\/10.1111\/imm.13443.","journal-title":"Immunology"},{"issue":"5","key":"5652_CR4","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s10067-022-06149-4","volume":"41","author":"LJ Jara","year":"2022","unstructured":"Jara LJ, Vera-Lastra O, Mahroum N, et\u00a0al. Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune\/inflammatory syndrome expand. Clin Rheumatol. 2022;41(5):1603\u20139. https:\/\/doi.org\/10.1007\/s10067-022-06149-4.","journal-title":"Clin Rheumatol"},{"key":"5652_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102898","volume":"132","author":"Y Rodr\u00edguez","year":"2022","unstructured":"Rodr\u00edguez Y, Rojas M, Beltr\u00e1n S, et\u00a0al. Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. J Autoimmun. 2022;132: 102898. https:\/\/doi.org\/10.1016\/j.jaut.2022.102898.","journal-title":"J Autoimmun"},{"key":"5652_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-024-02217-w","author":"V Sanker","year":"2024","unstructured":"Sanker V, Mylavarapu M, Gupta P, Syed N, Shah M, Dondapati VVK. Post COVID-19 vaccination medium vessel vasculitis: a systematic review of case reports. Infection. 2024. https:\/\/doi.org\/10.1007\/s15010-024-02217-w.","journal-title":"Infection"},{"issue":"10","key":"5652_CR7","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/ijd.16063","volume":"61","author":"G Avallone","year":"2022","unstructured":"Avallone G, Quaglino P, Cavallo F, et\u00a0al. SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review. Int J Dermatol. 2022;61(10):1187\u2013204. https:\/\/doi.org\/10.1111\/ijd.16063.","journal-title":"Int J Dermatol"},{"issue":"8","key":"5652_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15651","volume":"35","author":"S Shakoei","year":"2022","unstructured":"Shakoei S, Kalantari Y, Nasimi M, et\u00a0al. Cutaneous manifestations following COVID-19 vaccination: a report of 25 cases. Dermatol Ther. 2022;35(8): e15651. https:\/\/doi.org\/10.1111\/dth.15651.","journal-title":"Dermatol Ther"},{"issue":"5","key":"5652_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000373","volume":"109","author":"C Sohrabi","year":"2023","unstructured":"Sohrabi C, Mathew G, Maria N, et\u00a0al. The scare 2023 guideline: updating consensus surgical case report (SCARE) guidelines. Int J Surg. 2023;109(5): 1136. https:\/\/doi.org\/10.1097\/JS9.0000000000000373.","journal-title":"Int J Surg"},{"issue":"10","key":"5652_CR10","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.jiph.2021.06.021","volume":"14","author":"J Kong","year":"2021","unstructured":"Kong J, Cuevas-Castillo F, Nassar M, et\u00a0al. Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: case report. J Infect Public Health. 2021;14(10):1392\u20134. https:\/\/doi.org\/10.1016\/j.jiph.2021.06.021.","journal-title":"J Infect Public Health"},{"issue":"1","key":"5652_CR11","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1111\/1346-8138.16940","volume":"51","author":"S Yamamoto","year":"2024","unstructured":"Yamamoto S, Koga H, Tsutsumi M, et\u00a0al. Bullous pemphigoid associated with prodromal-phase by repeated COVID-19 vaccinations. J Dermatol. 2024;51(1):e6\u20137. https:\/\/doi.org\/10.1111\/1346-8138.16940.","journal-title":"J Dermatol"},{"issue":"5","key":"5652_CR12","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.12788\/cutis.0772","volume":"111","author":"DE Mustin","year":"2023","unstructured":"Mustin DE, Huffaker TB, Feldman RJ. New-onset pemphigoid gestationis following COVID-19 vaccination. Cutis. 2023;111(5):E2\u20134. https:\/\/doi.org\/10.12788\/cutis.0772.","journal-title":"Cutis"},{"issue":"8","key":"5652_CR13","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/ddg.15114","volume":"21","author":"J Hinterseher","year":"2023","unstructured":"Hinterseher J, Hertl M, Didona D. Autoimmune skin disorders and SARS-CoV-2 vaccination\u2014A meta-analysis. J Dtsch Dermatol Ges. 2023;21(8):853\u201361. https:\/\/doi.org\/10.1111\/ddg.15114.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"5652_CR14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s12105-023-01539-9","volume":"17","author":"D Rungraungrayabkul","year":"2023","unstructured":"Rungraungrayabkul D, Rattanasiriphan N, Juengsomjit R. Mucous membrane pemphigoid following the administration of COVID-19 vaccine. Head Neck Pathol. 2023;17(2):587\u20138. https:\/\/doi.org\/10.1007\/s12105-023-01539-9.","journal-title":"Head Neck Pathol"},{"issue":"2","key":"5652_CR15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/1346-8138.16687","volume":"50","author":"Y Nakahara","year":"2023","unstructured":"Nakahara Y, Yamane M, Sunada M, et\u00a0al. SARS-CoV-2 vaccine-triggered conversion from systemic lupus erythematosus (SLE) to bullous SLE and dipeptidyl peptidase 4 inhibitors-associated bullous pemphigoid. J Dermatol. 2023;50(2):162\u20135. https:\/\/doi.org\/10.1111\/1346-8138.16687.","journal-title":"J Dermatol"},{"issue":"2","key":"5652_CR16","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/odi.14468","volume":"30","author":"E Calabria","year":"2024","unstructured":"Calabria E, Antonelli A, Lavecchia A, et\u00a0al. Oral mucous membrane pemphigoid after SARS-CoV-2 vaccination. Oral Dis. 2024;30(2):782\u20133. https:\/\/doi.org\/10.1111\/odi.14468.","journal-title":"Oral Dis"},{"issue":"11","key":"5652_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.25270\/wmp.2022.11.2225","volume":"68","author":"Z Guo","year":"2022","unstructured":"Guo Z, Wang Y, Tang H, et\u00a0al. Bullous pemphigoid after vaccination with the inactivated severe acute respiratory syndrome coronavirus 2 vaccine: two cases in China. Wound Manag Prev. 2022;68(11):22\u20135.","journal-title":"Wound Manag Prev"},{"key":"5652_CR18","doi-asserted-by":"publisher","DOI":"10.5070\/D328458525","author":"B Daines","year":"2022","unstructured":"Daines B, Madigan LM, Vitale PA, et\u00a0al. A new eruption of bullous pemphigoid following mRNA COVID-19 vaccination. Dermatol Online J. 2022. https:\/\/doi.org\/10.5070\/D328458525.","journal-title":"Dermatol Online J"},{"issue":"8","key":"5652_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15595","volume":"35","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Lang X, Guo S, et\u00a0al. Bullous pemphigoid after inactivated COVID-19 vaccination: case report. Dermatol Ther. 2022;35(8): e15595. https:\/\/doi.org\/10.1111\/dth.15595.","journal-title":"Dermatol Ther"},{"issue":"9","key":"5652_CR20","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.jfma.2022.02.017","volume":"121","author":"PA Fu","year":"2022","unstructured":"Fu PA, Chen CW, Hsu YT, et\u00a0al. A case of acquired hemophilia A and bullous pemphigoid following SARS-CoV-2 mRNA vaccination. J Formos Med Assoc. 2022;121(9):1872\u20136. https:\/\/doi.org\/10.1016\/j.jfma.2022.02.017.","journal-title":"J Formos Med Assoc"},{"key":"5652_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.834316","volume":"13","author":"R Russo","year":"2022","unstructured":"Russo R, Gasparini G, Cozzani E, et\u00a0al. Absolving COVID-19 vaccination of autoimmune bullous disease onset. Front Immunol. 2022;13: 834316. https:\/\/doi.org\/10.3389\/fimmu.2022.834316.","journal-title":"Front Immunol"},{"issue":"6","key":"5652_CR22","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1111\/jdv.17955","volume":"36","author":"WK Hung","year":"2022","unstructured":"Hung WK, Chi CC. Incident bullous pemphigoid in a psoriatic patient following mRNA-1273 SARS-CoV-2 vaccination. J Eur Acad Dermatol Venereol. 2022;36(6):e407\u20139. https:\/\/doi.org\/10.1111\/jdv.17955.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"5652_CR23","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1111\/jdv.17891","volume":"36","author":"M Pauluzzi","year":"2022","unstructured":"Pauluzzi M, Stinco G, Errichetti E. Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: a report and brief literature review. J Eur Acad Dermatol Venereol. 2022;36(4):e257\u20139. https:\/\/doi.org\/10.1111\/jdv.17891.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"5652_CR24","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/bjd.20890","volume":"186","author":"T Gambichler","year":"2022","unstructured":"Gambichler T, Hamdani N, Budde H, et\u00a0al. Bullous pemphigoid after SARS-CoV-2 vaccination: spike-protein-directed immunofluorescence confocal microscopy and T-cell-receptor studies. Br J Dermatol. 2022;186(4):728\u201331. https:\/\/doi.org\/10.1111\/bjd.20890.","journal-title":"Br J Dermatol"},{"issue":"1","key":"5652_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.annder.2021.07.008","volume":"149","author":"FZ Agharbi","year":"2022","unstructured":"Agharbi FZ, Eljazouly M, Basri G, et\u00a0al. Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine. Ann Dermatol Venereol. 2022;149(1):56\u20137. https:\/\/doi.org\/10.1016\/j.annder.2021.07.008.","journal-title":"Ann Dermatol Venereol"},{"issue":"2","key":"5652_CR26","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1111\/jdv.17722","volume":"36","author":"V Schmidt","year":"2022","unstructured":"Schmidt V, Blum R, M\u00f6hrenschlager M. Biphasic bullous pemphigoid starting after first dose and boosted by second dose of mRNA-1273 vaccine in an 84-year-old female with polymorbidity and polypharmacy. J Eur Acad Dermatol Venereol. 2022;36(2):e88\u201390. https:\/\/doi.org\/10.1111\/jdv.17722.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"5652_CR27","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1111\/jdv.17676","volume":"36","author":"J Young","year":"2022","unstructured":"Young J, Mercieca L, Ceci M, et\u00a0al. A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine. J Eur Acad Dermatol Venereol. 2022;36(1):e13\u20136. https:\/\/doi.org\/10.1111\/jdv.17676.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"5652_CR28","doi-asserted-by":"publisher","first-page":"e606","DOI":"10.1111\/1346-8138.16170","volume":"48","author":"K Nakamura","year":"2021","unstructured":"Nakamura K, Kosano M, Sakai Y, et\u00a0al. Case of bullous pemphigoid following coronavirus disease 2019 vaccination. J Dermatol. 2021;48(12):e606\u20137. https:\/\/doi.org\/10.1111\/1346-8138.16170.","journal-title":"J Dermatol"},{"issue":"1","key":"5652_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/cup.14104","volume":"49","author":"V Larson","year":"2022","unstructured":"Larson V, Seidenberg R, Caplan A, et\u00a0al. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination. J Cutan Pathol. 2022;49(1):34\u201341. https:\/\/doi.org\/10.1111\/cup.14104.","journal-title":"J Cutan Pathol"},{"issue":"3","key":"5652_CR30","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jaci.2021.06.026","volume":"148","author":"MM Tomayko","year":"2021","unstructured":"Tomayko MM, Damsky W, Fathy R, et\u00a0al. Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination. J Allergy Clin Immunol. 2021;148(3):750\u20131. https:\/\/doi.org\/10.1016\/j.jaci.2021.06.026.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"5652_CR31","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1016\/j.medcle.2021.05.004","volume":"157","author":"I P\u00e9rez-L\u00f3pez","year":"2021","unstructured":"P\u00e9rez-L\u00f3pez I, Moyano-Bueno D, Ruiz-Villaverde R. Bullous pemphigoid and COVID-19 vaccine. Medicina Cl\u00ednica (English Edition). 2021;157(10):e333\u20134.","journal-title":"Medicina Cl\u00ednica (English Edition)"},{"issue":"5","key":"5652_CR32","doi-asserted-by":"publisher","first-page":"590","DOI":"10.4103\/ijd.ijd_519_23","volume":"68","author":"NM Dawoud","year":"2023","unstructured":"Dawoud NM, Aslam H, Alshehri MA, Dawoud MM. COVID-19 vaccine-triggered bullous pemphigoid: two new cases from Saudi Arabia. Indian J Dermatol. 2023;68(5):590. https:\/\/doi.org\/10.4103\/ijd.ijd_519_23.","journal-title":"Indian J Dermatol"},{"issue":"2","key":"5652_CR33","first-page":"730","volume":"33","author":"N Mulianto","year":"2023","unstructured":"Mulianto N, Hashfi AF. Bullous pemphigoid associated with Covid-19 vaccine in child: a case report. J Pak Assoc Dermatol. 2023;33(2):730\u20135.","journal-title":"J Pak Assoc Dermatol"},{"issue":"1","key":"5652_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4274\/jtad.galenos.2022.70883","volume":"17","author":"P \u00dcst\u00fcn","year":"2023","unstructured":"\u00dcst\u00fcn P, Sat\u0131lm\u0131\u015f A, K\u0131l\u0131\u00e7 \u0130\u0130, et\u00a0al. COVID-19 Vaccine induced bullous pemphigoid: case report and review of the literature. J Turk Acad Dermatol. 2023;17(1):27\u201330.","journal-title":"J Turk Acad Dermatol."},{"issue":"4","key":"5652_CR35","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4103\/1027-8117.358000","volume":"40","author":"YC Chao","year":"2022","unstructured":"Chao YC, Liu KL. New-onset bullous pemphigoid triggered by AstraZeneca COVID-19 vaccine. Dermatol Sin. 2022;40(4):245\u20136. https:\/\/doi.org\/10.4103\/1027-8117.358000.","journal-title":"Dermatol Sin"},{"issue":"6","key":"5652_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21608","volume":"186","author":"E Ailenei","year":"2022","unstructured":"Ailenei E, et\u00a0al. Bullous pemphigoid onset following Pfizer-BioNTech COVID-19 vaccine (COMIRNATY): coincidence or a new emerging adverse effect? Br J Dermatol. 2022;186(6): e251. https:\/\/doi.org\/10.1111\/bjd.21608.","journal-title":"Br J Dermatol"},{"key":"5652_CR37","doi-asserted-by":"crossref","unstructured":"17th Medical Dermatology Meeting, 13 January 2022. Br J Dermatol. 2022;186(6).","DOI":"10.1111\/bjd.21608"},{"key":"5652_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.103420","volume":"75","author":"F Alshammari","year":"2022","unstructured":"Alshammari F, Abuzied Y, Korairi A, et\u00a0al. Bullous pemphigoid after second dose of mRNA-(Pfizer-BioNTech) covid-19 vaccine: a case report. Ann Med Surg. 2022;75: 103420. https:\/\/doi.org\/10.1016\/j.amsu.2022.103420.","journal-title":"Ann Med Surg"},{"issue":"3","key":"5652_CR39","first-page":"200","volume":"21","author":"R Linares-Navarro","year":"2023","unstructured":"Linares-Navarro R, Ram\u00edrez GR, Perandones-Gonz\u00e1lez H, Rodr\u00edguez-Prieto M\u00c1. Bullous pemphigoid developed after the COVID-19 vaccine. Skinmed. 2023;21(3):200\u20132.","journal-title":"Skinmed"},{"issue":"2","key":"5652_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15241","volume":"35","author":"E Bostan","year":"2022","unstructured":"Bostan E, Yel B, Akdogan N, Gokoz O. New-onset bullous pemphigoid after inactivated Covid-19 vaccine: synergistic effect of the Covid-19 vaccine and vildagliptin. Dermatol Ther. 2022;35(2): e15241. https:\/\/doi.org\/10.1111\/dth.15241.","journal-title":"Dermatol Ther"},{"issue":"1","key":"5652_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15208","volume":"35","author":"M Dell'Antonia","year":"2022","unstructured":"Dell\u2019Antonia M, Anedda S, Usai F, Atzori L, Ferreli C. Bullous pemphigoid triggered by COVID-19 vaccine: rapid resolution with corticosteroid therapy. Dermatol Ther. 2022;35(1): e15208. https:\/\/doi.org\/10.1111\/dth.15208.","journal-title":"Dermatol Ther"},{"issue":"6","key":"5652_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15496","volume":"35","author":"CA Maronese","year":"2022","unstructured":"Maronese CA, Di Zenzo G, Genovese G, et\u00a0al. Reply to \u201cNew-onset bullous pemphigoid after inactivated Covid-19 vaccine: synergistic effect of the Covid-19 vaccine and vildagliptin.\u201d Dermatol Ther. 2022;35(6): e15496. https:\/\/doi.org\/10.1111\/dth.15496.","journal-title":"Dermatol Ther"},{"key":"5652_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102898","author":"Y Rodr\u00edguez","year":"2022","unstructured":"Rodr\u00edguez Y, Rojas M, Beltr\u00e1n S, et\u00a0al. Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. J Autoimmun. 2022. https:\/\/doi.org\/10.1016\/j.jaut.2022.102898.","journal-title":"J Autoimmun"},{"key":"5652_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1112823","author":"A Pira","year":"2023","unstructured":"Pira A, Sinagra JLM, Moro F, et\u00a0al. Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine. Front Med Lausanne. 2023. https:\/\/doi.org\/10.3389\/fmed.2023.1112823.","journal-title":"Front Med Lausanne"},{"issue":"14","key":"5652_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11143968","volume":"11","author":"X Huang","year":"2022","unstructured":"Huang X, Liang X, Zhang J, et\u00a0al. Pemphigus during the COVID-19 epidemic: infection risk, vaccine responses and management strategies. J Clin Med. 2022;11(14): 3968. https:\/\/doi.org\/10.3390\/jcm11143968.","journal-title":"J Clin Med"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05652-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-025-05652-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05652-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T19:05:47Z","timestamp":1767467147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-025-05652-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5652"],"URL":"https:\/\/doi.org\/10.1186\/s13256-025-05652-x","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for the case report as per the country\u2019s guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"1"}}